RIBOLIFE-B(06938): RBD7022 injection is about to start phase III clinical trials in China for the treatment of hyperlipidemia indications.

RIBOLIFE-B (06938) announced that the independently developed RBD7022 injection by the group has completed phase III clinical trial registration notification by the partner Qilu Pharmaceutical Co., Ltd. (Qilu Pharmaceutical) and is about to start phase III clinical trials. RBD7022 injection is a targeted siRNA drug against PCSK9. PCSK9 is an enzyme that plays a key role in regulating cholesterol levels in the body, especially low-density lipoprotein (LDL) cholesterol, commonly known as "LDL-C" or "bad cholesterol". It can be used as a treatment option for managing hypercholesterolemia, aiming to reduce the risk of cardiovascular diseases associated with high cholesterol levels. In December 2023, the company granted Qilu Pharmaceutical exclusive rights for the development, production, and commercialization of RBD7022 injection in mainland China, Hong Kong, and Macau.